Loading
AP
Adamis Pharmaceuticals Corp Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by WILLIAMS RICHARD C, was filed 28 May 2019.
Adamis Pharmaceuticals Corp: what insiders have been doing
Every trade that managers of Adamis Pharmaceuticals Corp disclose to SEC (Form 4) is tracked on this page. The company sits in the Healthcare & Pharma sector and is based in San Diego, United States. It was founded in 2006. The past year has been quiet: not a single insider filing for Adamis Pharmaceuticals Corp. The previous disclosure was published on 19 September 2023.
Looking back to 2016, when coverage begins, insiders filed 3 purchases and 64 sales.
Other companies in the same sector with recent insider buying flagged by our signals: Xenon Pharmaceuticals Inc. and Vivos Inc. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Insider Decl.
91
Thresholds
n/a
Buy Volume
€88,309
3 ops. · all time
Sell Volume
€768,649
64 ops. · all time
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2020FY ended December 2020 · cache
Income statement
Revenue14.7M
Gross profit-1.3M-9% margin
Net income-23.6M-160.2% margin
Last declaration on 19 September 2023
Declarations91 total
729,200 shares0Common StockSEC:0001387131-23-011359:0
3,138 sharesCommon StockSEC:0001839882-23-013975:0
8,745 sharesCommon StockSEC:0001839882-23-013976:0
177,194 sharesCommon StockSEC:0001839882-23-013974:0
177,194 sharesCommon StockSEC:0001839882-23-013976:1
250,000 sharesCommon StockSEC:0001387131-22-006577:0
3,603 shares@ US$0.612817.5% of flowCommon StockSEC:0001387131-22-003860:0
8,199 shares@ US$0.603615.3% of flowCommon StockSEC:0001387131-22-003863:0
11,859 shares@ US$0.600115.4% of flowCommon StockSEC:0001387131-22-003862:0
10,490 shares@ US$0.599314.6% of flowCommon StockSEC:0001387131-22-003861:0
13,554 shares@ US$0.78582.5% of flowCommon StockSEC:0001387131-21-011778:0
47,870 shares@ US$0.78585.4% of flowCommon StockSEC:0001387131-21-011775:0
35,553 shares@ US$0.78584.7% of flowCommon StockSEC:0001387131-21-011777:0
50,757 shares@ US$0.78584.6% of flowCommon StockSEC:0001387131-21-011776:0
27,822 sharesCommon StockSEC:0001593968-21-000577:0
22,258 sharesCommon StockSEC:0001593968-21-000580:0
22,258 sharesCommon StockSEC:0001593968-21-000579:0
13,911 sharesCommon StockSEC:0001593968-21-000578:0
35,000 shares@ US$0.405227.0% of flowCommon StockSEC:0001593968-20-002245:0
35,000 shares@ US$0.4013.3% of flowCommon StockSEC:0001593968-20-002246:0
8,532 shares@ US$0.40613.3% of flowCommon StockSEC:0001593968-20-002228:0
5,333 shares@ US$0.406113.3% of flowCommon StockSEC:0001593968-20-002229:0
10,665 shares@ US$0.40615.6% of flowCommon StockSEC:0001593968-20-002230:0
7,229 shares@ US$0.40615.6% of flowCommon StockSEC:0001593968-20-002231:0
8,532 shares@ US$0.40616.4% of flowCommon StockSEC:0001593968-20-002232:0
25 of 91 declarations
About Adamis Pharmaceuticals Corp
Adamis Pharmaceuticals Corp. (ticker: ADMP) is a U.S.-based specialty biopharmaceutical company listed on the NASDAQ market in the United States. For French, Belgian, and Swiss investors, it sits in the healthcare/pharma segment with a small-cap profile: the company focuses on developing and commercializing specialty treatments in therapeutic areas such as severe allergic reactions, opioid overdose, respiratory conditions, and inflammatory disease. Its corporate headquarters are in San Diego, California, which places it within one of the most established biotechnology clusters in the United States.
The company was founded in the mid-2000s and has been led for many years by Dennis J. Carlo, Ph.D., a co-founder who has served as President and Chief Executive Officer since 2006. That long tenure matters from an analyst perspective because it suggests continuity in strategy through multiple development, regulatory, and commercialization phases. Adamis has historically been a product-focused biotech rather than a broad platform company, and its operating model reflects a deliberate emphasis on targeted, clinically relevant products rather than a large diversified portfolio.
Read moreShow less
Its core business lines are centered on two marketed products and one development program. SYMJEPI® is an FDA-approved epinephrine injection for the emergency treatment of acute allergic reactions, including anaphylaxis. ZIMHI® is an FDA-approved naloxone injection for the emergency treatment of opioid overdose. The company also highlights APC-400 (tempol), a capsule in development. From an investment standpoint, this is a concentrated pipeline: it offers clarity, but it also means the business is highly dependent on the commercial traction, regulatory standing, and execution quality of a limited number of assets.
In competitive terms, Adamis operates in markets that are crowded and dominated by larger pharmaceutical players and established specialty companies. Its relative edge is not scale, but rather product focus, clinical relevance, and the potential utility of its emergency-care offerings. At the same time, the company’s smaller size means it is more exposed to commercialization risk, funding constraints, and regulatory or operational setbacks than larger peers.
Recent corporate context appears to be especially important. The company’s website references merger-related communications involving DMK Pharmaceuticals and also notes prior NASDAQ compliance updates and product-related news. For investors, that means ADMP should be viewed as a NASDAQ-listed U.S. healthcare name with event-driven characteristics: the equity is tied not only to product execution, but also to corporate actions, compliance milestones, and strategic transactions. In short, Adamis is a niche specialty pharma story with real medical relevance, but it remains a higher-risk, lower-scale investment opportunity that requires careful monitoring of capital structure, regulatory developments, and business combination news.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
